New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 4, 2013
09:19 EDTCPWR, LCC, ALU, CCL, CUK, ARIA, INGOn The Fly: Pre-market Movers
HIGHER: Alcatel-Lucent (ALU), up 9.4% following upgraded to Buy at Deutsche Bank... ING Group (ING), up 3.6% after upgrade at BNP Paribas... ARIAD (ARIA), up 6.5% after updating on R&D and commercial progress for a newly launched drug and one under development... Navidea Biopharmaceuticals (NAVB), up 7.8% after its Lymphoseek meets primary efficacy endpoint in trial... LOWER: Compuware (CPWR), down 2.1%, after warning its fourth quarter earnings and revenue are likely to sharply miss consensus estimates... US Airways (LCC), down 1.8% following downgrade to Neutral from Buy at Bank of America Merrill Lynch... Carnival (CCL), down 1.7% after its "Triumph" cruiseship reported to have broken loose from its dock in Alabama.
News For CPWR;LCC;ALU;CCL;CUK;ARIA;ING From The Last 14 Days
Check below for free stories on CPWR;LCC;ALU;CCL;CUK;ARIA;ING the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
September 29, 2014
07:36 EDTARIAARIAD presents updated clinical data on AP26113
ARIAD Pharmaceuticals announced updated clinical results on its investigational tyrosine kinase inhibitor, AP26113, in patients with advanced non-small cell lung cancer from an ongoing Phase 1/2 trial. These study results show sustained anti-tumor activity of AP26113 in patients with anaplastic lymphoma kinase positive NSCLC, including patients with active brain metastases. The updated Phase 1/2 trial now contains more mature data of AP26113, including increasing depth and durability of response in ALK+ NSCLC patients, as well as additional safety data. The updated results were presented on Saturday, September 27 at the 2014 European Cancer Congress held in Madrid, Spain. A total of 137 patients have been enrolled in the ongoing Phase 1/2 trial in the United States and Europe. The objectives of the Phase 1 portion of the trial were to characterize the safety and tolerability of AP26113, pharmacokinetics, and preliminary anti-tumor activity and to determine the recommended dose for further study of AP26113 in subsequent clinical trials. The trial used an open-label, dose-escalating design. The Phase 2 portion of the trial consists of five expansion cohorts. The data presented at ESMO focus on the 79 patients with a history of ALK+ NSCLC tumors in the entire trial. Fifty-six of these patients currently remain on study treatment.
September 25, 2014
10:33 EDTCCLOptions with decreasing implied volatility
Options with decreasing implied volatility: VHC RPRX SFLY VNET YHOO RHT KMX BBBY CCL ACN
September 24, 2014
07:11 EDTCCLCarnival demand, pricing trends appear set to rebound, says Stifel
Subscribe for More Information
September 23, 2014
11:32 EDTCUK, CCLCarnival says COO Buckelew expands role, relocating to China
Subscribe for More Information
10:47 EDTCCLCarnival sees 2014 CapEx around $3B, similiar in 2015 and 2016
Subscribe for More Information
10:27 EDTCCLCarnival signs of Caribbean recovery bodes well for peers, says Wells Fargo
Subscribe for More Information
10:25 EDTCCLCarnival sees higher dry-dock expense in 2015 as 10c headwind
Subscribe for More Information
09:21 EDTCCLCarnival reports Q3 net revenue yields up 1.8%
Subscribe for More Information
09:20 EDTCCLCarnival sees Q4 non-GAAP EPS 15c-19c, consensus 21c
Subscribe for More Information
09:20 EDTCCLCarnival sees FY15 net cruise costs excluding fuel per ALBD to increase 3%
The increase will be due primarily to a significantly higher level of dry-dock days scheduled next year to install new air emissions technology as well as other technology designed to improve fuel efficiency. The company expects the exhaust gas cleaning system or scrubber technology will be installed on approximately 70 percent of its fleet by 2016, thus enabling the company to meet the 2015 stricter air emissions standards as well as mitigate escalating fuel costs that will result from the new requirements. The company anticipates the new regulations will result in higher fuel costs in 2015 of approximately $0.10 per share with that increase expected to be reduced by half in 2016 and mostly offset in 2017 based on the system roll-out. Also, in 2016, the company will revert back to a more normalized dry-dock schedule, which will offset approximately half of the increase in 2015 net cruise costs excluding fuel.
09:19 EDTCCLCarnival raises FY14 EPS to $1.84-$1.88 from $1.60-$1.75, consensus $1.75
Subscribe for More Information
09:17 EDTCCLCarnival: Strong close-in demand, higher onboard spending drove Q3 results
Subscribe for More Information
09:16 EDTCCLCarnival reports Q3 EPS $1.58, consensus $1.44
Subscribe for More Information
September 22, 2014
15:06 EDTCCLNotable companies reporting before tomorrow's open
Subscribe for More Information
12:28 EDTCCLCarnival technical notes ahead of earnings
In the past three months the shares have performed inline with the broader averages. The trend has been strongly up since the low of early August and the shares are trading near the 52-week high of $41.89. That high would be a highly probable upside objective on a positive surprise. On better than expected news that strongly exceeds expectations there would be room for a breakout in price. Next resistance levels as potential upside objectives depending on the degree of positive surprise would be at $42.67, $44.42, and $46.86. If the news fails to meet expectations, downside objectives could be at the following support levels: $38.24, $36.54, and $35.64. There is a small short-base in the shares which could exacerbate downside reactions in the event of a negative surprise.
07:14 EDTALUGSM Association to hold a conference
Subscribe for More Information
September 19, 2014
11:18 EDTCCLCarnival October volatility elevated into Q2 and outlook
Carnival October call option implied volatility is at 26, January is at 21; compared to its 26-week average of 23 according to Track Data, suggesting large near term price movement into the expected release of Q2 results on September 23.
September 18, 2014
17:57 EDTARIAARIAD CEO buys 25K shares of company stock
Subscribe for More Information
07:52 EDTINGUBS Chair says litigation bigger worry than stress test, Bloomberg reports
Subscribe for More Information
06:39 EDTINGEuropean banks take out EUR83B of loans from central bank, NY Times says
European banks agreed to take out EUR83B in low interest loans from the European Central Bank, as part of a program in which all of the funds must be loaned to businesses or individuals, or repaid to the central bank within two years, according to The New York Times. Several analysts had said that they would be disappointed if banks took out less than EUR100B in loans, but a number of analysts said that a second round of the program, due to occur in December after stress tests have been completed, may be more popular, the newspaper stated. Publicly traded European banks include Banco Santander (SAN), Barclays (BCS), Credit Suisse (CS), Deutsche Bank (DB), HSBC (HSBC), ING Groep (ING), Lloyds Banking (LYG), Royal Bank of Scotland (RBS) and UBS (UBS). Reference Link
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use